References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailHealth outcomes of sarcopenia: a systematic review and meta-analysis.
Zaaria, M.; Pasleau, Françoise ULiege; Reginster, Jean-Yves ULiege et al

in Journal of Frailty & Aging (2017), 6 Suppl 1

Detailed reference viewed: 33 (3 ULiège)
Full Text
Peer Reviewed
See detailL'étude SarcoPhAge: devenir des sujets sarcopéniques après 2 ans de suivi.
Beaudart, Charlotte ULiege; Locquet, Médéa ULiege; Reginster, Jean-Yves ULiege et al

in L'Année Gérontologique (2017), 31(1), 42

Detailed reference viewed: 25 (2 ULiège)
Full Text
Peer Reviewed
See detailAnalyse des conséquences cliniques de la sarcopénie: une revue systématique et méta-analyse.
Beaudart, Charlotte ULiege; Zaaria, M.; Pasleau, F. et al

in L'année Gérontologique (2017), 31(1), 18

Detailed reference viewed: 47 (11 ULiège)
Full Text
Peer Reviewed
See detailOsteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.
Gielen, E.; Bergmann, P.; Bruyère, Olivier ULiege et al

in Calcified Tissue International (2017), 101(2), 111-31

In this consensus paper, the Belgian Bone Club aims to provide a state of the art on the epidemiology, diagnosis, and management of osteoporosis in frail individuals, including patients with anorexia ... [more ▼]

In this consensus paper, the Belgian Bone Club aims to provide a state of the art on the epidemiology, diagnosis, and management of osteoporosis in frail individuals, including patients with anorexia nervosa, patients on dialysis, cancer patients, persons with sarcopenia, and the oldest old. All these conditions may indeed induce bone loss that is superimposed on physiological bone loss and often remains under-recognized and under-treated. This is of particular concern because of the major burden of osteoporotic fractures in terms of morbidity, mortality, and economic cost. Therefore, there is an urgent need to appreciate bone loss associated with these conditions, as this may improve diagnosis and management of bone loss and fracture risk in clinical practice. [less ▲]

Detailed reference viewed: 24 (12 ULiège)
Full Text
Peer Reviewed
See detailReliability of muscle strength measures obtained with a hand-held dynamometer in an elderly population.
Buckinx, Fanny ULiege; Croisier, Jean-Louis ULiege; Reginster, Jean-Yves ULiege et al

in Clinical Physiology & Functional Imaging (2017), 37(3), 332-40

BACKGROUND: The objective of this study was to assess the reliability of a hand-held dynamometer for isometric strength measurements among nursing home residents. METHODS: The isometric muscle strength of ... [more ▼]

BACKGROUND: The objective of this study was to assess the reliability of a hand-held dynamometer for isometric strength measurements among nursing home residents. METHODS: The isometric muscle strength of nursing home residents was assessed for eight different muscle groups, using a hand-held dynamometer, the MicroFET2 device. Strength measurements were performed at baseline and after 4 days by the same operator and after 8 days by a second operator. Intraclass coefficients (ICC) were computed to assess the relative reliability, whereas the minimal detectable change (MDC%) was calculated to assess the absolute reliability of the test-retest of the MicroFET2 used by one single operator or by two different ones. RESULTS: Thirty nursing home residents (75.0 +/- 11.2 years, 50% of women) were enrolled in this study. ICC of the test-retest with one single operator ranged from 0.60 (0.37-0.83) for the ankle extensors to 0.85 (0.74-0.95) for the elbow flexors. When considering the test-retest with two different operators, the ICC values ranged from 0.62 (0.41-0.84) for the ankle extensors to 0.87 (0.79-0.96) for the elbow extensors. For the absolute reliability, MDC% varies from 27.64 (elbow flexors) to 81.97 (ankle extensors) when performed in intra-observer. In interobserver condition, MDC%, respectively, varies from 24.38 (elbow extensors) 67.59 (ankle extensors). CONCLUSION: Using standardized protocol and standardized instructions to patients, a high relative and moderate absolute reliability was observed for all but ankle muscle groups, making this hand-held dynamometer a potential tool for research in the elderly population. [less ▲]

Detailed reference viewed: 60 (12 ULiège)
Full Text
Peer Reviewed
See detailPrevalence of concomitant bone and muscle wasting in elderly women from the SarcoPhAge cohort: preliminary results
Locquet, Médéa ULiege; Beaudart, Charlotte ULiege; Reginster, Jean-Yves ULiege et al

in Journal of Frailty & Aging (2017), 6(1), 18-23

Background: Recent studies suggest that bone and muscle wasting are closely interconnected. Objective: The aim was of this study is to assess the prevalence of osteoporosis in a population of women ... [more ▼]

Background: Recent studies suggest that bone and muscle wasting are closely interconnected. Objective: The aim was of this study is to assess the prevalence of osteoporosis in a population of women diagnosed with sarcopenia. Participants, setting and design: We analyzed cross-sectional data of women, aged 65 years and above, for whom bone mineral density was available at the time of inclusion in the SarcoPhAge (Sarcopenia and Physical impairment with advancing Age) cohort, an ongoing prospective study with the aim to assess consequences of sarcopenia. Measurements: Muscle strength was evaluated with a hydraulic hand-dynamometer, appendicular lean mass and bone mineral density by Dual-Energy X-Ray Absorptiometry and physical performance by the Short Physical Performance Battery test (SPPB). Sarcopenia was diagnosed according to the European Working Group on Sarcopenia in Older People definition, i.e. a low muscle mass plus either low muscle strength or low physical performance. A bone mineral density T-score equal to or below -2.5SD at the lumbar spine, at the total hip or at the femoral neck was used to define osteoporosis (World Health Organization definition). Results: A total of 126 women aged 74.38±6.32 years were included. Among them, 26 were assessed with sarcopenia (20.6%) and 34 (27.0%) with osteoporosis. There were more osteoporotic women among sarcopenic subjects (46.1%) than among non-sarcopenic subjects (22.0%) (p-value=0.011). A significant lower appendicular lean mass index was observed in osteoporotic women (p-value=0.025). We also observed, in osteoporotic subjects, a lower muscle strength (p-value=0.023). Numerical values of bone mineral density were lower in the sarcopenic population but the differences did not reach the level of statistical significance. Conclusion: Our study demonstrated that muscle mass and strength are lower in patients with osteoporosis. Prospective changes in bone and muscle mass will be investigated during the follow-up of our cohort. [less ▲]

Detailed reference viewed: 84 (33 ULiège)
Full Text
Peer Reviewed
See detailThe role of calcium supplementation in healthy musculoskeletal ageing - An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis ans Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF)
Harvey, N.C.; Biver, E.; Kaufman, J.-M. et al

in Osteoporosis International (2017), 28(2), 447-62

Abstract The place of calcium supplementation, with or without concomitant vitamin D supplementation, has been much debated in terms of both efficacy and safety. There have been numerous trials and meta ... [more ▼]

Abstract The place of calcium supplementation, with or without concomitant vitamin D supplementation, has been much debated in terms of both efficacy and safety. There have been numerous trials and meta-analyses of supplementation for fracture reduction, and associations with risk of myocardial infarction have been suggested in recent years. In this report, the product of an expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF), we review the evidence for the value of calcium supplementation, with or without vitamin D supplementation, for healthy musculoskeletal ageing.We conclude that (1) calcium and vitamin D supplementation leads to a modest reduction in fracture risk, although population-level intervention has not been shown to be an effective public health strategy; (2) supplementation with calcium alone for fracture reduction is not supported by the literature; (3) side effects of calcium supplementation include renal stones and gastrointestinal symptoms; (4) vitamin D supplementation, rather than calcium supplementation, may reduce falls risk; and (5) assertions of increased cardiovascular risk consequent to calciumsupplementation are not convincingly supported by current evidence. In conclusion, we recommend, on the basis of the current evidence, that calcium supplementation, with concomitant vitamin D supplementation, is supported for patients at high risk of calcium and vitamin D insufficiency, and in those who are receiving treatment for osteoporosis. [less ▲]

Detailed reference viewed: 49 (16 ULiège)
Full Text
Peer Reviewed
See detailPharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the Chondroitin versus Celecoxib versus placebo trial (CONCEPT)
Reginster, Jean-Yves ULiege; Dudler, J; Blicharski, T et al

in Annals of the Rheumatic Diseases (2017), 0n line

Objectives : Chondroitin sulfate 800 mg/day (CS) pharmaceutical-grade in the management of symptomatic knee osteoarthritis consistent with the European Medicines Agency guideline. Methods: A prospective ... [more ▼]

Objectives : Chondroitin sulfate 800 mg/day (CS) pharmaceutical-grade in the management of symptomatic knee osteoarthritis consistent with the European Medicines Agency guideline. Methods: A prospective, randomised, 6-month, 3-arm, double-blind, double-dummy, placebo and celecoxib (200 mg/day)-controlled trial assessing changes in pain on a Visual Analogue Scale (VAS) and in the Lequesne Index (LI) as coprimary endpoints. Minimal-Clinically Important Improvement (MCII), Patient-Acceptable Symptoms State (PASS) were used as secondary endpoints. Results: 604 patients (knee osteoarthritis) diagnosed according to American College of Rheumalogy (ACR) criteria, recruited in five European countries and followed for 182 days. CS and celecoxib showed a greater significant reduction in pain and LI than placebo. In the intention-to-treat (ITT) population, pain reduction in VAS at day 182 in the CS group (−42.6 mm) and in celecoxib group (−39.5 mm) was significantly greater than the placebo group (−33.3 mm) (p=0.001 for CS and p=0.009 for celecoxib), while no difference observed between CS and celecoxib. Similar trend for the LI, as reduction in this metric in the CS group (−4.7) and celecoxib group (−4.6) was significantly greater than the placebo group (−3.7) (p=0.023 for CS and p=0.015 for celecoxib), no difference was observed between CS and celecoxib. Both secondary endpoints (MCII and PASS) at day 182 improved significantly in the CS and celecoxib groups. All treatments demonstrated excellent safety profiles. Conclusion: A 800 mg/day pharmaceutical-grade CS is superior to placebo and similar to celecoxib in reducing pain and improving function over 6 months in symptomatic knee osteoarthritis (OA) patients. This formulation of CS should be considered a first-line treatment in the medical management of knee OA. [less ▲]

Detailed reference viewed: 14 (2 ULiège)
Full Text
Peer Reviewed
See detailMeeting the Needs of Mothers During the Postpartum Period: Using Co-Creation Workshops to Find Technological Solutions.
Slomian, Justine ULiege; Emonts, Patrick ULiege; Vigneron, Lara ULiege et al

in JMIR Research Protocols (2017), 6(5), 76

BACKGROUND: The postnatal period is associated with many new needs for mothers. OBJECTIVE: The aim of this study was to find technological solutions that meet the needs of mothers during the year ... [more ▼]

BACKGROUND: The postnatal period is associated with many new needs for mothers. OBJECTIVE: The aim of this study was to find technological solutions that meet the needs of mothers during the year following childbirth. METHODS: Two co-creation workshops were undertaken with parents and professionals. The aim of the first workshop was to create a list of all the criteria the proposed solution would have to address to meet the needs of mothers after childbirth. The aim of the second workshop was to create solutions in response to the criteria selected during the first workshop. RESULTS: Parents and health professionals want solutions that include empathy (ie, to help fight against the feelings of abnormality and loneliness), that help mothers in daily life, that are personalized and adapted to different situations, that are educational, and that assures some continuity in their contact with health professionals. In practice, we found that parents and professionals think the solution should be accessible to everyone and available at all times. To address these criteria, technology experts proposed different solutions, such as a forum dedicated to the postpartum period that is supervised by professionals, a centralized website, a system of videoconferencing, an online exchange group, a "gift voucher" system, a virtual reality app, or a companion robot. CONCLUSIONS: The human component seems to be very important during the postnatal period. Nevertheless, technology could be a great ally in helping mothers during the postpartum period. Technology can help reliably inform parents and may also give them the right tools to find supportive people. However, these technologies should be tested in clinical trials. [less ▲]

Detailed reference viewed: 28 (4 ULiège)
Full Text
Peer Reviewed
See detailRelationship between low bone mineral density and fractures with incident cardiovascular disease: a systematic review and meta-analysis.
VERONESE, B.; STUBBS, B.; CREPALDI, G. et al

in Journal of Bone and Mineral Research (2017), 32

An increasing evidence base suggests that low bone mineral density (BMD) and fractures are associated with cardiovascular disease (CVD). We conducted a systematic review and meta-analysis summarizing the ... [more ▼]

An increasing evidence base suggests that low bone mineral density (BMD) and fractures are associated with cardiovascular disease (CVD). We conducted a systematic review and meta-analysis summarizing the evidence of low BMD and fractures as risk factors for future CVD. Two independent authors searched major databases from inception to August 1, 2016, for longitudinal studies reporting data on CVD incidence (overall and specific CVD) and BMD status and fractures. The association between low BMD, fractures, and CVD across longitudinal studies was explored by calculating pooled adjusted hazard ratios (HRs) 95% confidence intervals (CIs) with a random-effects meta-analysis. Twenty-eight studies (18 regarding BMD and 10 fractures) followed a total of 1,107,885 participants for a median of 5 years. Taking those with higher BMD as the reference, people with low BMD were at increased risk of developing CVD during follow-up (11 studies; HR¼1.33; 95%CI, 1.27 to 1.38; I2¼53%), after adjusting for a median of eight confounders. This finding was confirmed using a decrease in one standard deviation of baseline BMD (9 studies; HR¼1.16; 95% CI, 1.09 to 1.24; I2¼69%). The presence of fractures at baseline was associated with an increased risk of developing CVD (HR¼1.20; 95% CI, 1.06 to 1.37; I2¼91%). Regarding specific CVDs, low BMD was associated with an increased risk of developing coronary artery disease, cerebrovascular conditions, and CVD-associated death. Fractures at baseline was associated with an increased risk of cerebrovascular conditions and death due to CVD. In conclusion, low BMD and fractures are associated with a small, but significant increased risk of CVD risk and possibly death. © 2017 American Society for Bone and Mineral Research. [less ▲]

Detailed reference viewed: 21 (2 ULiège)
Full Text
Peer Reviewed
See detailMind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.
Harvey, N.C.W.; McCloskey, E.V.; Mitchell, P.J. et al

in Osteoporosis International (2017), 28

This narrative review considers the key challenges facing healthcare professionals and policymakers responsible for providing care to populations in relation to bone health. These challenges broadly fall ... [more ▼]

This narrative review considers the key challenges facing healthcare professionals and policymakers responsible for providing care to populations in relation to bone health. These challenges broadly fall into four distinct themes: (1) case finding and management of individuals at high risk of fracture, (2) public awareness of osteoporosis and fragility fractures, (3) reimbursement and health system policy and (4) epidemiology of fracture in the developing world. Findings from cohort studies, randomised controlled trials, systematic reviews and meta-analyses, in addition to current clinical guidelines, position papers and national and international audits, are summarised, with the intention of providing a prioritised approach to delivery of optimal bone health for all. Systematic approaches to case-finding individuals who are at high risk of sustaining fragility fractures are described. These include strategies and models of care intended to improve case finding for individuals who have sustained fragility fractures, those undergoing treatment with medicines which have an adverse effect on bone health and people who have diseases, whereby bone loss and, consequently, fragility fractures are a common comorbidity. Approaches to deliver primary fracture prevention in a clinically effective and costeffective manner are also explored. Public awareness of osteoporosis is low worldwide. If older people are to be more proactive in the management of their bone health, that needs to change. Effective disease awareness campaigns have been implemented in some countries but need to be undertaken in many more. A major need exists to improve awareness of the risk that osteoporosis poses to individuals who have initiated treatment, with the intention of improving adherence in the long term. A multisector effort is also required to support patients and their clinicians to have meaningful discussions concerning the risk-benefit ratio of osteoporosis treatment. With regard to prioritisation of fragility fracture prevention in national policy, there is much to be done. In the developing world, robust epidemiological estimates of fracture incidence are required to inform policy development. As the aging of the baby boomer generation is upon us, this review provides a comprehensive analysis of how bone health can be improved worldwide for all. [less ▲]

Detailed reference viewed: 20 (2 ULiège)
Full Text
Peer Reviewed
See detailVitamin D status correction in Saudi Arabia: an experts' consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO)
Al-Daghri, N; Al-Saleh, Y; Aljohani, N et al

in Archives of Osteoporosis (2017), 12

Background :Vitamin D deficiency is common in the Middle East and in Saudi Arabia, in particular. While several international recommendations on the management of vitamin D deficiency have been documented ... [more ▼]

Background :Vitamin D deficiency is common in the Middle East and in Saudi Arabia, in particular. While several international recommendations on the management of vitamin D deficiency have been documented and practiced globally, these recommendations should be adapted to the conditions of the Middle Eastern region. To address this challenge, the Prince Mutaib Chair for Biomarkers of Osteoporosis (PMCO) in King Saud University (KSU), Riyadh, KSA, together with local experts and in cooperation with the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), organized a panel that ormulated unified recommendations in the diagnosis and treatment of vitamin D deficiency in the region. Methods: The selection of local and international experts commenced during the 2nd International Vitamin D Symposium conducted in Riyadh, Saudi Arabia, last January 20-–21, 2016. Reviews of the most recent literature were done, and face-to-face meetings were conducted for revisions and final recommendations.Results: Vitamin D sufficiency is defined as circulating serum 25(OH)D ≥50 nmol (≥20 ng/ml) for the general population and vitamin D adequacy as serum 25(OH)D >75 nmol/L l (>30 ng/ml) for the frail and osteoporotic elderly. Despite overwhelming prevalence of vitamin D deficiency, universal screening is not recommended. Recommendations for the general population, children, pregnant/lactating women, postmenopausal women, the elderly, and those with subsequent metabolic diseases were provided. Results: Vitamin D sufficiency is defined as circulating serum 25(OH)D ≥50 nmol (≥20 ng/ml) for the general population and vitamin D adequacy as serum 25(OH)D >75 nmol/L l (>30 ng/ml) for the frail and osteoporotic elderly. Despite overwhelming prevalence of vitamin D deficiency, universal screening is not recommended. Recommendations for the general population, children, pregnant/lactating women, post-menopausal women, the elderly, and those with subsequent metabolic diseases were provided. Conclusion: Vitamin D supplementation/correction is advised in all persons whose serum 25(OH)D falls below 50 nmol/l (20 ng/ml), and achieving a target of 75 nmol/l (30 ng/ml) is particularly suited for frail, osteoporotic, and older patients. Conductingwelldesigned clinical trials in the region that will address economic implications and investigations on the treatment persistence and compliance to vitamin D treatment in the region are encouraged. [less ▲]

Detailed reference viewed: 9 (1 ULiège)
Full Text
Peer Reviewed
See detailEnergy and nutrient content of food served and consumed by nursing home residents
Buckinx, Fanny ULiege; ALLEPAERTS, Sophie ULiege; PAQUOT, Nicolas ULiege et al

in the journal of nutrition, health & aging (2017), 21(6), 727-32

Objective: The aim of this study was to compare energy and protein content of the served food with the actual intake from the food consumed by nursing home residents. This study also aimed to compare food ... [more ▼]

Objective: The aim of this study was to compare energy and protein content of the served food with the actual intake from the food consumed by nursing home residents. This study also aimed to compare food intake and dietary allowances. Design: This is a cross sectional study. Setting: This study was performed in nursing homes. Participants: Residents of these 2 nursing homes were eligible for the study if they agreed to participate and if they meet the selection criteria (to be older than 65 years and have a regular texture diet). Measurement: Nutrient content of the served food and real food consumption was calculated for all meals during a 5-day period by precise weighting method. Difference between consumed and served dietary content was evaluated by the Chi² test. Results: Seventy-four Belgian nursing home residents (75% of women, 85.8 ± 7.04 years on average) were included in this study. These subjects had a mean body mass index of 24.9 ± 4.83 kg/m². The mean energy content of the served food was 1783.3 ± 125.7 kcal per day. However, residents did not eat the whole of the meals and the actual energy content of the consumed food was significantly less (1552.4 ± 342.1 kcal per day; p<.001). The average protein content of the food served was equal to 0.96 ± 0.20 g/kg/day and the average consumption of protein by the residents was 0.88 ± 0.25 g/kg/day. The difference between protein served and consumed was also significant (p=.04). Moreover, people considered as well nourished, eating significantly more energy than the others (p=.04). Conclusion: Meals served in nursing homes are not entirely consumed by their residents. As expected, the energy consumed are lower in subjects considered as malnourished or at risk of malnutrition. [less ▲]

Detailed reference viewed: 38 (19 ULiège)
Full Text
Peer Reviewed
See detailQualité des médicaments antipaludéens et caractéristiques des pharmacies des territoires périurbains de Kinshasa
Mavungu Landu, Don Jethro ULiege; Liégeois, Sophie; Manzambi Kuwekita, Joseph ULiege et al

Poster (2016, December 14)

Contexte: Le paludisme causé par le Plasmodium falciparum demeure un problème majeur de santé publique. Le traitement avec des antipaludiques de bonne qualité est une composante importante dans le ... [more ▼]

Contexte: Le paludisme causé par le Plasmodium falciparum demeure un problème majeur de santé publique. Le traitement avec des antipaludiques de bonne qualité est une composante importante dans le contrôle de cette maladie. Cependant en Afrique centrale, plus de 25% des médicaments serait contrefaits ou de qualité inférieure, situation qui serait encore plus dramatique dans les territoires périurbains. Méthode: Dans le contexte ci-mentionné, une étude préliminaire et prospective a été menée dans la zone de santé de Mont Ngafula 1 située dans les territoires périurbains de la Ville de Kinshasa durant la période allant du 22 février au 17 mars 2016. Treize échantillons de poudre pour suspension d’artéméther et de luméfantrine ont été collectés. L’analyse de la qualité de ces médicaments a été réalisée au moyen de méthodes séparatives génériques utilisant la technique de chromatographie liquide à haute performance couplé à un détecteur à barrettes de diodes. Une caractérisation a été également effectuée dans 127 établissements pharmaceutiques sur base des normes édictées par le Ministère de la Santé Publique congolais. Résultats: Les résultats des analyses des échantillons d’antimalariques (ou antipaludéens) montre que presque la moitié des poudres pour suspension d’artéméther et de luméfantrine ne contenait pas la concentration prévue en artéméther et/ou en luméfantrine. Par ailleurs, le résultat des observations évoque qu’aucun établissement pharmaceutique ne respecte l’ensemble des normes du Ministère de la Santé Publique. [less ▲]

Detailed reference viewed: 291 (19 ULiège)
Full Text
Peer Reviewed
See detailMacro-economic factors influencing the architectural business model shift in the pharmaceutical industry
Dierks, Raphaela Marie Louisa ULiege; Bruyère, Olivier ULiege; Reginster, Jean-Yves ULiege et al

in Expert Review of Pharmacoeconomics & Outcomes Research (2016), 16(5), 571-8

Introduction: Technological innovations, new regulations, increasing costs of drug productions and new demands are only few key drivers of a projected alternation in the pharmaceutical industry and its ... [more ▼]

Introduction: Technological innovations, new regulations, increasing costs of drug productions and new demands are only few key drivers of a projected alternation in the pharmaceutical industry and its underlying business model. Despite significant articles in the press, there is little medical and economic evidence on the rationale driving the transformation from the traditional Research & Development (R&D) model to new alternative business models, such as Mergers & Acquisitions (M&A). The purpose of this review is to understand the macro-economic factors responsible for the revolution of the pharmaceutical business model, by understanding the needs, desires, new behavioral patterns, but also challenges within the industry. Considering these changes will be the key to possessing a competitive advantage over the market players. Areas covered: Existing literature on new macro-economic factors changing the pharmaceutical landscape has been reviewed to present a clear image of the current market environment. Expert commentary: Literature and media sources show that pharmaceutical companies are facing an architectural alteration in their business model, with more M&A deals and collaborations headlining the papers. Although Q1 2016 did show a major slowdown in M&A deals by volume since 2013 (with deal cancellations of Pfizer and Allergan, or the downfall of Valeant) pharmaceutical analysts remain confident that this shortfall was a consequence of the equity market volatility. It seems likely that the shift to an M&A model will become apparent during the remainder of 2016, with deal announcements such as Abbott Laboratories, AbbVie and Sanofi worth USD 45billion [1] showing the appetite of big pharma companies to shift from the fully vertical integrated business model to more horizontal business models. [less ▲]

Detailed reference viewed: 78 (20 ULiège)